Saturday 17 October 2026
Export IRON’s income statement to Excel — free account
Disc Medicine, Inc.
IRON Healthcare Biotechnology
In the quarter to June 2026, EPS grew 2.53%, free cash flow grew 7.83% and total debt rose 106.5%, each against the same quarter a year earlier.
56.80
0.15
+0.26%
Follow IRON
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 294.00 | 68.40 | 15.00 | 16.05 | 25.60 | 30.82 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 378.00 | 572.55 | 93.00 | 66.61 | 77.60 | 99.50 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 33 | 46 | 74 | 84 | 155 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | — | (41) | (36) | (47) | (76) | (109) | (212) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | 0 | (41) | (36) | (47) | (76) | (109) | (212) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | (5) | (8) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (27.02) | (40.97) | (45.05) | (3.42) | (3.96) | (6.01) | |||||
| Cash flow | — | — | — | — | (21.64) | (31.36) | (40.67) | (3.29) | (3.40) | (5.11) | |||||
| Capex | — | — | — | — | (0.01) | (0.08) | (0.15) | 0.00 | (0.02) | (0.03) | |||||
| Free cash flow | — | — | — | — | (21.65) | (31.44) | (40.81) | (3.30) | (3.42) | (5.14) | |||||
| Book value | — | — | — | — | (14.46) | (73.12) | 169.97 | 15.47 | 16.07 | 20.96 | |||||
| Shares, m | — | — | — | — | 2 | 1 | 1 | 22 | 28 | 35 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (33) | (28) | (42) | (73) | (94) | (180) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | (1) | (1) | |||||
| Free cash flow | — | — | — | — | (33) | (28) | (42) | (74) | (94) | (181) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (20) | 77 | 176 | 344 | 470 | 767 | ||||
| Total debt | — | — | — | — | 10 | 0 | 1 | — | 28 | 29 | |||||
| Net debt | — | — | — | — | 5 | (88) | (195) | (360) | (462) | (762) | |||||
| Shareholders’ equity | — | — | — | — | (22) | (64) | 177 | 345 | 444 | 740 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (490.89) | (71.42) | (32.01) | (26.90) | (25.29) | (32.55) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 186.80 | 83.59 | (83.32) | (29.30) | (27.73) | (35.86) | |||||
Negative figures in brackets.
Charts ten years each
Disc Medicine, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| AUPH Aurinia Pharmaceuticals Inc | $2.2B | 6.9× | 16.5× | +18.87% (above 0%: growing) | +81.25% (above 0%: growing) | +19.08% (above 0%: growing) | 92.12% | 48.19% | Compare |
| HRMY Harmony Biosciences Holdings, Inc. | $2.2B | 12.2× | 9.4× | +30.32% (above 0%: growing) | +88.41% (above 0%: growing) | +16.53% (above 0%: growing) | 75.81% | 34.18% | Compare |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | — (loss-making) | — (loss-making) | −60.10% (below 0%: shrinking) | n/m | −32.03% (below 0%: shrinking) | (49.82%) | (1,759.69%) | Compare |
| VRDN Viridian Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | +278.67% (above 0%: growing) | n/m | −41.39% (below 0%: shrinking) | 100.00% | (44,460.56%) | Compare |
| IRON Disc Medicine, Inc. | $2.2B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | |
| FTRE Fortrea Holdings Inc. | $2.2B | — (loss-making) | — (loss-making) | −4.52% (below 0%: shrinking) | n/m | +53.15% (above 0%: growing) | 20.52% | 2.18% | Compare |
| NVAX Novavax, Inc. | $2.1B | — (loss-making) | — (loss-making) | −76.30% (below 0%: shrinking) | n/m | +42.95% (above 0%: growing) | 74.87% | (96.84%) | Compare |
| VCEL Vericel Corporation | $2.1B | 83.6× | 76.8× | +22.48% (above 0%: growing) | n/m | +17,503.70% (above 0%: growing) | 72.82% | 0.56% | Compare |
| Median of peers | $2.2B | 12.2× | 16.5× | +7.18% | — | +17.80% | 75.34% | (48.14%) |
Disc Medicine, Inc. (IRON) key facts
- Disc Medicine, Inc. (IRON) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, IRON traded at $56.80, a market capitalization of $2.2 billion.
- Return on equity was −35.9% and debt-to-equity 0.09.